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Abstract
In The Netherlands, both an increase in and regional differences in erythromycin resistance of Campylobacter jejuni and Campylobacter coli
have been reported. To determine the accuracy of routine tests for erythromycin resistance, 48 erythromycin-resistant isolates from
various laboratories that participate in the Dutch surveillance of Campylobacter infections were reinvestigated. Initial susceptibility testing
for erythromycin had been performed by disk diffusion in six and MIC-based methods in two laboratories. Reinvestigation was carried
out using broth microdilution as a reference standard, as well as E-test and genetic resistance testing. Of 36 C. jejuni isolates reported by
the initial laboratories as erythromycin-resistant, four (11%) and ﬁve (14%) were conﬁrmed as erythromycin-resistant using broth
microdilution according to CLSI and EUCAST resistance criteria, respectively. Erythromycin resistance was found in eight of 12 (67%)
C. coli isolates according to both criteria. Results of E-tests were in accordance with these results in all isolates. Resistance-associated
mutations in the 23S rRNA gene (A2059G and A2058T) were found in all isolates showing high-level resistance, whereas none were
found in susceptible isolates. Routine determination of the erythromycin resistance of C. jejuni and C. coli shows unacceptable interlabora-
tory variation. In the absence of standardized protocols and interpretive criteria for disk diffusion, and while we await the development
of easily applicable and reliable methods for molecular resistance testing, the use of broth microdilution remains the best method.
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Introduction
Campylobacter contributes to considerable childhood morbidity
in developing countries and is one of the most common causes
of bacterial gastroenteritis in industrialized countries [1,2].
Additionally, travellers’ diarrhoea is often caused by Campylo-
bacter species [3,4]. In industrialized countries the most
frequently encountered Campylobacter species isolated from
diarrhoeal stools are Campylobacter jejuni and Campylobacter coli,
which account for > 98% of laboratory-conﬁrmed infections
[4,5]. Campylobacter infections are usually self-limiting,
but early treatment with erythromycin has been shown to
shorten the duration of diarrhoeal illness in children [6]. In
cases of severe or persistent illness and in immunocompro-
mised patients, Campylobacter infections can cause substantial
morbidity for which rapid and effective antibiotic treatment is
required. The treatment of choice is a macrolide antibiotic, such
as erythromycin, as ﬂuoroquinolone resistance has rapidly
increased during the last decade [5].
In Campylobacter, erythromycin resistance is mainly caused
by alterations of the erythromycin binding site in the 23S
rRNA unit of the ribosome, similar to those observed in
Helicobacter isolates [7]. Other mechanisms of resistance,
such as alterations of efﬂux pumps, can also be found in
Campylobacter isolates and have recently been reported to
act in synergy with the 23S rRNA mutation to confer high-
level erythromycin resistance [8,9]. In the Netherlands and
in most industrialized countries, resistance rates for erythro-
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mycin in Campylobacter spp. have remained stable at relatively
low levels, whereas higher resistance rates are reported in
southern Europe and some countries in Asia [10]. Infections
with erythromycin-resistant isolates have been reported in
association with a ﬁve-fold increased risk of invasive illness
or death in a Danish study [11].
A recent report on Campylobacter laboratory surveillance
in the Netherlands indicated that erythromycin resistance
levels among C. jejuni and C. coli apparently increased from
stable levels of 1.5% and 2.0%, respectively, in 2002, to 3.9%
and 6.3%, respectively, in 2003 [4,12]. Furthermore, regional
differences in the prevalence of erythromycin resistance were
reported [13]. A national survey demonstrated that disk
diffusion was the test most frequently applied to determine
Campylobacter resistance in surveillance laboratories, but
results were not conﬁrmed by MIC-based methods (van der
Beek et al., submitted for publication). Therefore, we hypoth-
esized that the apparent increase in erythromycin resistance
and the regional differences in resistance levels merely
reﬂected inaccurate resistance testing. To study this, erythro-
mycin-resistant C. jejuni and C. coli strains from a 2002–2003
case-control study nested in the routine laboratory surveil-
lance of Campylobacter were reinvestigated using MIC-based
methods and molecular resistance testing.
Materials and Methods
Campylobacter isolates
All Campylobacter isolates included in the present study were
derived from a case-control study carried out in 2002–2003
(CaSa Study) [14,15] and from routine laboratory surveil-
lance of Campylobacter and Salmonella. In total, 18 regional
public health laboratories collected 3169 Campylobacter iso-
lates. The participating laboratories performed species identi-
ﬁcation and susceptibility testing according to local
procedures. Conﬁrmation of species identiﬁcation was per-
formed by PCR-restriction fragment length polymorphism
(RFLP) analysis of the 16S rRNA and 23S rRNA genes at a
central laboratory [16,17].
Among 2823 isolates tested for erythromycin susceptibil-
ity, 112 (4%) were reported to be resistant [12]. Among all
resistant isolates, a selection of 48 C. jejuni and C. coli isolates
from 12 laboratories were available for further analysis at
the Leiden University Medical Centre (LUMC). In the LUMC,
susceptibility for erythromycin was reinvestigated using broth
microdilution and E-test. An erythromycin-resistant C. jejuni
isolate (MIC value > 256 mg/L) that had been isolated from a
diarrheic stool sample at the Clinical Microbiology Labora-
tory at the LUMC (isolate 6534) was included as a resistant
control isolate. C. jejuni ATCC 33560 was included as an
erythromycin-susceptible control isolate.
In vitro susceptibility tests
Broth microdilution was performed using custom-made mic-
rotitre plates from Trek Diagnostic Systems (East Grinstead,
UK) according to CLSI guideline M45-A [18]. The two-fold
dilution range of erythromycin concentrations in the plates
was 0.5–64 mg/L. Brieﬂy, colonies from 24–48-h cultures were
suspended in PBS 0.9% to a turbidity of 0.5 McF and subse-
quently diluted 200 times in cation-adjusted Mueller–Hinton
broth with 2–2.5% lysed horse blood. Fifty microlitre of this
suspension was added to 96-well microtitre plates containing
antibiotics. Plates were incubated in a micro-aerobic atmo-
sphere at 37 C. MIC values were determined after 48 h of
incubation.
All isolates were also tested for susceptibility to
erythromycin using E-test (AB Bome´rieux, Solna, Sweden).
Colonies from 24–48-h cultures were suspended in PBS 0.9%
to a turbidity of 0.5 McF. This suspension was plated on a
Mueller–Hinton agar plate with 5% sheep blood (Biome´rieux
BV, Boxtel, the Netherlands) and an E-test strip was put on
each plate after the surface of the plate had dried. Plates
were incubated in a micro-aerobic atmosphere at 37 C. MIC
values were determined after 48 h of incubation.
Classiﬁcation of isolates as resistant (R) was based on MIC
values after 48 h of incubation using criteria from the CLSI
(R: MIC ‡ 32 mg/L) and EUCAST (R: MIC > 4 mg/L for C. jejuni
and wildtype £ 16 mg/L for C. coli; http://www.srga.org/
eucastwt/MICTAB/index.html) [18].
Erythromycin resistance testing by 23S rRNA sequencing
Detection of single nucleotide polymorphisms in the 23S
rRNA sequence was performed by sequence analysis of the
nucleotides 1909–2257 (position of nucleotides reported as
the E. coli equivalents) in the 23S rRNA as previously
described [19]. The 23S rRNA fragment was ampliﬁed using
primers Ar69fw and Ery23sr (Ar69fw: GTAACTATAACGGT
CCTAAG nt. 1909–1928; Ery23sr: GACCGCCCCAGTCAA
ACT nt. 2257–2227). Cycle sequencing reactions were per-
formed using the same primers and an ABI Prism 3100 Genetic
Analyser (Applied Biosystem, Inc. Foster City, CA, USA).
Results
Using broth microdilution and applying CLSI criteria for
resistance, four of the 36 (11%) C. jejuni isolates previously
reported as erythromycin-resistant were found to be
erythromycin-resistant (Table 1). According to EUCAST
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criteria, ﬁve of the 36 (14%) isolates were erythromycin-
resistant. The isolate that was classiﬁed differently by CLSI
and EUCAST criteria (isolate 1306) had an MIC value of
16 mg/L and was classiﬁed as intermediate-susceptible
according to CLSI criteria and resistant according to EU-
CAST criteria. Of the 12 C. coli isolates reported to be resis-
tant, eight (67%) were resistant according to both CLSI and
EUCAST criteria using broth microdilution (Table 1).
Using E-test, CLSI criteria revealed four (11%) and EU-
CAST criteria revealed ﬁve (14%) of the 36 C. jejuni isolates
to be erythromycin-resistant (Table 1). The isolate that was
classiﬁed differently by CLSI and EUCAST criteria had an
MIC value of 12 mg/L and was classiﬁed as intermediate-sus-
ceptible according to CLSI and resistant according to EU-
CAST. Of the 12 C. coli isolates reported to be resistant,
eight (67%) were resistant according to CLSI and EUCAST
criteria using E-test (Table 1).
The MIC values as determined by E-test differed on aver-
age two-fold from the MIC values established by broth
microdilution, but the classiﬁcation as resistant was identical
using both methods (Table 1). MIC values determined after
24 h of incubation of the E-test resulted in 1.5- to two-fold
lower MIC values in 12 isolates (25%) compared with results
after 48 h of incubation (data not shown).
TABLE 1. Results of MIC-based erythromycin susceptibility tests for 50 Campylobacter isolates
Sample Species
Broth microdilution
Interpretation
according to E-test
Interpretation
according to
(MIC, mg/L) CLSIa EUCASTb (MIC, mg/L) CLSIa EUCASTb
1095 C. jejuni £ 0.50 S S 0.50 S S
1122 C. jejuni £ 0.50 S S 0.50 S S
1132 C. jejuni £ 0.50 S S 0.50 S S
1141 C. jejuni £ 0.50 S S 0.50 S S
1142 C. jejuni £ 0.50 S S 0.50 S S
1219 C. jejuni £ 0.50 S S 0.50 S S
2824 C. jejuni £ 0.50 S S 0.50 S S
5065 C. jejuni £ 0.50 S S 0.50 S S
5689 C. jejuni £ 0.50 S S 0.50 S S
1109 C. jejuni £ 0.50 S S 0.75 S S
1145 C. jejuni £ 0.50 S S 0.75 S S
1147 C. jejuni £ 0.50 S S 0.75 S S
1292 C. jejuni £ 0.50 S S 0.75 S S
2195 C. jejuni £ 0.50 S S 0.75 S S
2205 C. jejuni £ 0.50 S S 0.75 S S
2274 C. jejuni £ 0.50 S S 0.75 S S
2892 C. jejuni £ 0.50 S S 0.75 S S
4215 C. jejuni £ 0.50 S S 0.75 S S
1143 C. jejuni £ 0.50 S S 1.0 S S
1174 C. jejuni £ 0.50 S S 1.0 S S
5044 C. jejuni £ 0.50 S S 1.0 S S
5129 C. jejuni £ 0.50 S S 1.0 S S
1221 C. jejuni £ 0.50 S S 1.5 S S
1768 C. jejuni 1.0 S S 0.50 S S
1144 C. jejuni 1.0 S S 0.75 S S
0998 C. jejuni 1.0 S S 1.0 S S
3553 C. jejuni 1.0 S S 1.0 S S
1043 C. jejuni 1.0 S S 1.5 S S
1146 C. jejuni 1.0 S S 1.5 S S
1031 C. jejuni 2.0 S S 1.5 S S
5052 C. jejuni 2.0 S S 4.0 S S
1306 C. jejuni 16.0 I R 12.0 I R
2704 C. jejuni > 64 R R > 256 R R
3715 C. jejuni > 64 R R > 256 R R
4222 C. jejuni > 64 R R > 256 R R
4713 C. jejuni > 64 R R > 256 R R
3576 C. coli 2.0 S S 2.0 S S
1190 C. coli 2.0 S S 3.0 S S
1034 C. coli 2.0 S S 4.0 S S
5131 C. coli 4.0 S S 6.0 S S
0328 C. coli > 64 R R 256 R R
0878 C. coli > 64 R R 256 R R
3629 C. coli > 64 R R 256 R R
4188 C. coli > 64 R R > 256 R R
4312 C. coli > 64 R R > 256 R R
5127 C. coli > 64 R R > 256 R R
5675 C. coli > 64 R R > 256 R R
5708 C. coli > 64 R R > 256 R R
ATCC 33560 C. jejuni 1.0 S S 1.0 S S
Leiden 6534 C. jejuni > 64 R R > 256 R R
S, susceptible; I, intermediate-susceptible; R, resistant.
aCLSI breakpoints for C. jejuni and C. coli: S £ 8 mg/L, R ‡ 32 mg/L.
bEUCAST breakpoints for C. jejuni: S £ 4 mg/L, R > 4 mg/L; for C. coli only wild-type distribution given: wild-type £ 16 mg/L.
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To determine the presence of resistance-associated
mutations, 23S rRNA genotyping was performed on a subset
of 28 isolates comprising all the different MIC values found
among the isolates upon retesting (Table 2). Nucleotide
sequence analysis showed the wild-type genotype (AA at
nucleotides 2058 and 2059) in all isolates that were susceptible
in broth microdilution (n = 16) and in one C. jejuni isolate with
an MIC value of 16 mg/L (intermediate-susceptible according
to CLSI criteria and resistant according to EUCAST criteria).
An A2059G mutation was found in all resistant C. coli
isolates (n = 8) and in three resistant C. jejuni isolates (all
MIC > 64 mg/L). In one resistant C. jejuni isolate and in our
resistant clinical control isolate (C. jejuni Leiden 6534) an
A2058T mutation was found (both MIC > 64 mg/L).
Discussion
In this study, 48 Campylobacter isolates collected in a national
surveillance survey and reported to be resistant to erythro-
mycin were reinvestigated using broth microdilution as the
reference standard in order to evaluate the efﬁcacy of rou-
tine methods for determining erythromycin resistance.
Depending on the application of CLSI or EUCAST criteria,
only 11–14% of the C. jejuni isolates and 67% of the C. coli
isolates were classiﬁed as resistant upon reinvestigation. This
is worrisome because false-positive resistance tests may have
important clinical consequences, particularly in cases of iso-
lates with resistance to both erythromycin and ciproﬂoxacin,
where physicians may be unnecessarily forced to choose less
effective or more toxic antibiotics for the treatment of
Campylobacter infections.
Several hypotheses can explain the discrepancies in the
determination of erythromycin resistance. Firstly, differences
in the methods applied for susceptibility testing can cause
different susceptibility results. Most participating laboratories
(eight of ten laboratories from which data were available)
used varying protocols for disk diffusion as methods for rou-
tine susceptibility testing in Campylobacter isolates (van der
Beek et al., submitted for publication). The disk diffusion test
is relatively inexpensive and easily applicable and has been
investigated as a susceptibility test for Campylobacter with
varying results [20–22]. The British Society for Antimicrobial
Chemotherapy (BSAC) and the CLSI advise that disk diffusion
should be used to screen for resistance and that results
should be conﬁrmed by MIC determined methods [18,23].
When applying disk diffusion, critical zone diameters adapted
from those of non-fastidious organisms should be applied
with caution because the incubation conditions of such organ-
isms differ from those required for Campylobacter. The effect
of a basic antibiotic such as erythromycin decreases in an
environment with high CO2 levels and can result in falsely
increased MIC values [20,22,24]. Therefore, interpretation of
Campylobacter susceptibility test results from disk diffusion,
other than according to CLSI protocol, or without conﬁrma-
tion by MIC-based methods, remains unreliable. In a study by
Mevius et al., interpretative criteria were proposed in associa-
tion with EUCAST epidemiological cut-off values based on
disk diffusion and broth microdilution according to CLSI pro-
tocol on a limited collection of 89 isolates (Mevius DJ, Veld-
man K, van Pelt W, Heres L, Mulder B, Wagenaar JA.
Determination of Interpretive Criteria for Susceptibility Tests
of Campylobacter spp. 14th International Conference on Cam-
pylobacter, Helicobacter and Related Organisms, 2007; p. 28.).
The E-test is an MIC-based technique that is readily avail-
able and easy to apply in many laboratories. In several stud-
ies, E-test results were found to agree with results of broth
or agar dilution assays, but in none of these studies was the
E-test compared with current CLSI-approved methods for
broth microdilution [25–28]. In this study, the MIC values as
determined by E-test were comparable with those found by
broth microdilution. Susceptibility classiﬁcation based on
E-test results was in accordance with that of broth microdi-
lution in all isolates. MIC values determined by E-test after
TABLE 2. Results of phenotypical and genotypical suscep-
tibility tests for 28 selected Campylobacter isolates
Sample Species
Broth dilution
microdilution
(MIC: mg/L)
E-test
(MIC: mg/L)
Genotype
(nt 2058–2059)a
5689 C. jejuni £ 0.50 0.50 AA
2274 C. jejuni £ 0.50 0.75 AA
2195 C. jejuni £ 0.50 0.75 AA
5129 C. jejuni £ 0.50 1.0 AA
5044 C. jejuni £ 0.50 1.0 AA
1768 C. jejuni 1.0 0.50 AA
0998 C. jejuni 1.0 1.0 AA
3553 C. jejuni 1.0 1.0 AA
1043 C. jejuni 1.0 1.5 AA
1031 C. jejuni 2.0 1.5 AA
5052 C. jejuni 2.0 4.0 AA
1306 C. jejuni 16.0 12.0 AA
4713 C. jejuni > 64 > 256 AG
4222 C. jejuni > 64 > 256 AG
3715 C. jejuni > 64 > 256 AG
2704 C. jejuni > 64 > 256 TA
3576 C. coli 2.0 2.0 AA
1190 C. coli 2.0 3.0 AA
1034 C. coli 2.0 4.0 AA
5131 C. coli 4.0 6.0 AA
3629 C. coli > 64 256 AG
0878 C. coli > 64 256 AG
0328 C. coli > 64 256 AG
5708 C. coli > 64 > 256 AG
5675 C. coli > 64 > 256 AG
5127 C. coli > 64 > 256 AG
4312 C. coli > 64 > 256 AG
4188 C. coli > 64 > 256 AG
ATCC 33560 C. jejuni 1.0 1.0 AA
Leiden 6534 C. jejuni > 64 > 256 TA
aAA, wild-type; A2059G, mutant; A2058T, mutant.
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24 h of incubation (data not shown) were lower than those
obtained after 48 h of incubation in 25% of the isolates and
would lead to higher false susceptibility rates. This demon-
strates that an adequate incubation period is important for
reliable resistance determination.
Secondly, the use of different breakpoints may have played
a role in causing the discrepancies. The two laboratories that
used MIC-based methods (E-test and broth microdilution,
respectively) used lower critical MIC values than the CLSI
and EUCAST criteria.
Finally, instability of erythromycin resistance may have
played a role in the discrepancy between our study ﬁndings
and the initial susceptibility testing results. The stability of
macrolide resistance after subculturing Campylobacter isolates
has been studied previously. Restoration of susceptibility was
observed in one of seven erythromycin-resistant isolates
after 55 subcultures in the absence of antibiotic selection
pressure [7]. In Helicobacter pylori isolates, instability rates of
0%, 10% and 45% were reported in three different studies
[29–31]. Instability may have led to an in vitro underestima-
tion of resistance as we tested after more subculture rounds
than the original laboratories. However, the number of
subcultures was not very high (< 20) in this study, making
instability and reversion to susceptibility not very likely.
Campylobacter isolates displaying resistance caused by the
presence of mechanisms other than 23S rRNA mutations
seem to constitute a minority of all resistant isolates, although
a recent report indicated that an efﬂux mechanism can act in
synergy with the 23S rRNA mutation to confer high-level
erythromycin resistance [7–9,32]. The most common resis-
tance-associated 23S rRNA mutations in this and other studies
have been detected at nucleotide positions 2058 (A ﬁ C,
A ﬁ T) and 2059 (A ﬁ G) of the 23S rRNA. They lead to
cross-resistance to macrolide and lincosamide antibiotics
[7,10,33]. In this study, resistance-associated mutations were
found in all resistant isolates except one C. jejuni isolate with
an MIC value of 16 mg/L. All investigated susceptible strains
showed a wild-type genotype. The A2058T mutation that was
detected in two C. jejuni isolates has been previously associ-
ated with low-level resistance to macrolides in a C. coli isolate
(MIC 8 mg/L), but this isolate was heterozygous for this muta-
tion [34].
The isolates in this study appeared to carry only a single
mutation and had MIC values > 64 mg/L. It is possible that in
the near future genotypic detection of resistance will come
into use more commonly than phenotypical tests. For erythro-
mycin resistance in Helicobacter, less cumbersome methods
than sequence analysis have been described for detection
of the most frequently occurring resistance-associated
mutations, such as PCR-RFLP analysis and real-time PCR, even
on stool samples [34–37]. For Campylobacter, such methods
have recently been introduced for isolates originating from
clinical samples [38], but not yet for direct application on stool
samples. In comparison with phenotypic tests, determination
of genotypic resistance is relatively fast, especially for slow-
growing isolates. In addition, less interlaboratory or interassay
variability is expected when using this method. However,
more knowledge of resistance mutations may be necessary
before this method can be routinely applied.
This study had some limitations. It represents a retrospec-
tive analysis and it included only those isolates reported as
resistant by local laboratories. Nevertheless, because a rele-
vant proportion of isolates appeared to be susceptible to
erythromycin using broth microdilution, our selection included
isolates with varying levels of susceptibility to erythromycin.
In conclusion, the determination of the erythromycin
resistance of C. jejuni and C. coli is inaccurate according to
current practice. The standardization of frequently used sus-
ceptibility testing methods, such as disk diffusion, must be
mandatory if we are to obtain reliable results for fastidious
and micro-aerophilic organisms such as Campylobacter. In the
absence of standardized protocols and interpretive to crite-
ria for disk diffusion, broth dilution remains the best
method.
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